Search Results

/TPI (35 mg/m 2 twice daily) and oxaliplatin (85 mg/m 2 ) before undergoing concurrent chemoradiation (standard-of-care radiation dose of 5,040 cGy will be used at all participating study sites) with carboplatin (area under the curve, 2) and paclitaxel (50

10 found that pembrolizumab + BCA 101 (bifunctional EGFR monoclonal antibody with TGFβ modulator; N=20) resulted in a 44% ORR. Non–5-FU combinations with pembrolizumab are also emerging. The KEYNOTE-B10 trial combined carboplatin, paclitaxel, and

,040 cGy will be used at all participating study sites) with carboplatin (area under the curve, 2) and paclitaxel (50 mg/m 2 ) for 6 weeks, followed by surgery. FTD/TPI will be self-administered (in tablet form) twice daily by study participants and

will be used at all participating study sites) with carboplatin (area under the curve, 2) and paclitaxel (50 mg/m2) for 6 weeks, followed by surgery. FTD/TPI will be self-administered (in tablet form) twice daily by study participants and documented in

The study’s first arm was placebo + carboplatin/paclitaxel followed by placebo as maintenance. Arm 2 was veliparib + carboplatin/paclitaxel followed by placebo. Arm 3 was veliparib + carboplatin/paclitaxel followed by veliparib maintenance. An

dose of 5,040 cGy will be used at all participating study sites) with carboplatin (area under the curve, 2) and paclitaxel (50 mg/m2) for 6 weeks, followed by surgery. FTD/TPI will be self-administered (in tablet form) twice daily by study participants

/TPI (35 mg/m 2 twice daily) and oxaliplatin (85 mg/m 2 ) before undergoing concurrent chemoradiation (standard-of-care radiation dose of 5,040 cGy will be used at all participating study sites) with carboplatin (area under the curve 2) and paclitaxel (50

of PD-L1. The combination of carboplatin and paclitaxel was administered every 3 weeks for 4 cycles, but the disease progressed in the right lung. She was then referred to Ohio State University, and 200 mg of pembrolizumab was administered

randomised controlled trial . Lancet Oncol 2006 ; 7 : 719 – 727 . 13. Strauss GM Herndon J Maddaus MA . Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung

CIPN (NCI-CTCAE ≥2) and No Pain Versus With Pain Comparison of CIPN Subgroups Among Different Chemotherapy Types The 2 largest chemotherapy-type cohorts (paclitaxel and oxaliplatin) were selected for group comparisons. There were significant